Logo

⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Official Title: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian

Study ID: NCT02822157

Conditions

Ovarian Epithelial Cancer

Interventions

Olaparib
carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly

Study Description

Brief Summary: This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

UZLeuven, Leuven, , Belgium

Contact Details

Name: Ignace Vergote

Affiliation: Universitaire Ziekenhuizen KU Leuven

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: